NRx Pharmaceuticals, Inc.
NRXP
$3.37
-$0.10-2.88%
NASDAQ
| 06/30/2026 | 03/31/2026 | ||||
|---|---|---|---|---|---|
| Revenue | 3.09% | 8.65% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 3.09% | 8.65% | |||
| Cost of Revenue | 6.97% | 54.66% | |||
| Gross Profit | -2.52% | -24.00% | |||
| SG&A Expenses | 24.44% | -16.55% | |||
| Depreciation & Amortization | 4.76% | 50.00% | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 30.71% | 4.29% | |||
| Operating Income | -36.92% | -3.35% | |||
| Income Before Tax | -1,055.24% | -497.22% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -1,055.24% | -497.22% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -1,055.24% | -497.22% | |||
| EBIT | -36.92% | -3.35% | |||
| EBITDA | -37.25% | -2.92% | |||
| EPS Basic | -892.76% | -456.45% | |||
| Normalized Basic EPS | -886.33% | 64.90% | |||
| EPS Diluted | -892.76% | -456.45% | |||
| Normalized Diluted EPS | -886.33% | 64.90% | |||
| Average Basic Shares Outstanding | 16.47% | 11.62% | |||
| Average Diluted Shares Outstanding | 16.47% | 11.62% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||